DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
PharmAbbie is developing drugs targeted at the pet market based on existing human formulations. The company is concentrating on therapeutic categories including pain and inflammation, infections, diarrhea, dermatology, and cardiovascular problems, intended to provide safe, efficacious and easy-to-administer drugs to improve the quality of life of companion animals and their guardians.
PharmAbbie
Groton, CT
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.